Get the Stockscreener App
1.89
1.05%
-0.02
After Hours:
1.89
In 8 Bio Inc stock is traded at $1.89, with a volume of 61,131.
It is down -1.05% in the last 24 hours and up +6.18% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$1.91
Open:
$1.9
24h Volume:
61,131
Relative Volume:
0.24
Market Cap:
$18.46M
Revenue:
-
Net Income/Loss:
$-20.66M
P/E Ratio:
-0.4019
EPS:
-4.7022
Net Cash Flow:
$-14.63M
1W Performance:
+9.88%
1M Performance:
+6.18%
6M Performance:
-10.00%
1Y Performance:
-72.16%
1-Day Range:
$1.82
$1.99
1-Week Range:
$1.70
$2.05
52-Week Range:
$1.17
$7.50
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.89 | 18.46M | 0 | -20.66M | -14.63M | -4.7022 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Adicet Bio (NASDAQ: ACET) outlines 2025 loss and cash runway into 2027 - Stock Titan
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028 - Stock Titan
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
KALA BIO (NASDAQ: KALA) signs exclusive Researgency AI license and $55M Younet option - Stock Titan
Bank license renewal backs BIO-key (NASDAQ: BKYI) biometric growth - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio (NASDAQ: ENTX) refines EB613 Phase 3 osteoporosis trial timeline - Stock Titan
bioAffinity Technologies (NASDAQ: BIAF) shows asthma and COPD diagnostic data - Stock Titan
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
Adicet Bio Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Belite Bio Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
Inmune Bio furnishes corporate presentation detailing CORDStrom and XPro1595 development plans - TradingView
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
TRML SEC FilingsTourmaline Bio 10-K, 10-Q, 8-K Forms - Stock Titan
New CyPath Lung validation study at BAMC by bioAffinity (BIAF) - Stock Titan
TELA SEC FilingsTela Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
BioMarin’s top execs schedule four investor events in March - Stock Titan
Construction giant brings drug tests in-house with fingerprint scans at UK sites - Stock Titan
BIO-key to secure Mozambique digital payments for 36.6M people - Stock Titan
Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan
Axsome Therapeutics, Inc. SEC 10-K Report - TradingView
BioMarin (BMRN) grows 2025 revenue 13% and guides 2026 EPS to $4.95–$5.15 - Stock Titan
Inclement weather delays PROCEPT BioRobotics Q4 call, Investor Day - Stock Titan
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Gossamer Bio reports PROSERA topline: missed primary 6MWD endpoint but secondary endpoints and high-risk subgroup favored seralutinib - TradingView
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Opaleye Group reports 1.256M shares in Q32 Bio (NASDAQ: QTTB) - Stock Titan
Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update - Stock Titan
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
CORDStrom Phase III RDEB data to be detailed by INmune Bio (NASDAQ: INMB) - Stock Titan
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
Q32 Bio (NASDAQ: QTTB) raises $10.5M to fund alopecia trials - Stock Titan
Point72 entities report 2.9% Korro Bio (KRRO) stake in amended 13G - Stock Titan
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
[SCHEDULE 13G/A] GRI Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):